Kuo Gee-Hong, Prouty Catherine, DeAngelis Alan, Shen Lan, O'Neill David J, Shah Chandra, Connolly Peter J, Murray William V, Conway Bruce R, Cheung Peter, Westover Lori, Xu Jun Z, Look Richard A, Demarest Keith T, Emanuel Stuart, Middleton Steven A, Jolliffe Linda, Beavers Mary Pat, Chen Xin
Drug Discovery Division, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, P.O. Box 300, Raritan, New Jersey 08869, USA.
J Med Chem. 2003 Sep 11;46(19):4021-31. doi: 10.1021/jm030115o.
Attempts to design the macrocyclic maleimides as selective protein kinase C gamma inhibitors led to the unexpected discovery of a novel series of potent and highly selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Palladium-catalyzed cross-coupling reactions were used to synthesize the key intermediates 17 and 22 that resulted in the synthesis of novel macrocycles. All three macrocyclic series (bisindolyl-, mixed 7-azaindoleindolyl-, and bis-7-azaindolylmaleimides) were found to have submicromolar inhibitory potency at GSK-3beta with various degrees of selectivity toward other protein kinases. To gain the inhibitory potency at GSK-3beta, the ring sizes of these macrocycles may play a major role. To achieve the selectivity at GSK-3beta, the additional nitrogen atoms in the indole rings may contribute to a significant degree. Overall, the bis-7-azaindolylmaleimides 28 and 29 exhibited little or no inhibitions to a panel of 50 protein kinases. Compound 29 almost behaved as a GSK-3beta specific inhibitor. Both 28 and 29 displayed good potency in GS cell-based assay. Molecular docking studies were conducted in an attempt to rationalize the GSK-3beta selectivity of azaindolylmaleimides.
将大环马来酰亚胺设计为选择性蛋白激酶Cγ抑制剂的尝试,意外地发现了一系列新型的、强效且高度选择性的糖原合酶激酶-3β(GSK-3β)抑制剂。钯催化的交叉偶联反应被用于合成关键中间体17和22,进而合成了新型大环化合物。发现所有三个大环系列(双吲哚基、混合的7-氮杂吲哚吲哚基和双-7-氮杂吲哚基马来酰亚胺)对GSK-3β均具有亚微摩尔级的抑制效力,且对其他蛋白激酶具有不同程度的选择性。为了获得对GSK-3β的抑制效力,这些大环的环大小可能起主要作用。为了实现对GSK-3β的选择性,吲哚环中的额外氮原子可能在很大程度上起作用。总体而言,双-7-氮杂吲哚基马来酰亚胺28和29对一组50种蛋白激酶几乎没有或没有抑制作用。化合物29几乎表现为一种GSK-3β特异性抑制剂。28和29在基于GS细胞的测定中均显示出良好的效力。进行了分子对接研究,试图阐明氮杂吲哚基马来酰亚胺对GSK-3β的选择性。